Deutsche Bank Downgrades United Therapeutics To Hold

According to Deutsche Bank, United Therapeutics UTHR is downgraded to Hold. Deutsche Bank said that this morning United Therapeutics announced that the combination trial Freedom - C(2) for Oral Remodulin did not hit primary endpoint. “We expect stock to remain weak due to this news. We calculate fair value of UTHR at $53 in the absence of Oral Remodulin.” United Therapeutics closed yesterday at $48.76.